US and UK authorities are monitoring pharmaceutical spending and disclosure in their respective jurisdictions, seeking transparency in the payments pharmaceutical companies make to the healthcare sector.
Payments covered include those made to patient groups, healthcare associations, charities and training providers.
Pfizer’s $60m to DOJ
The US Department of Justice (DOJ)
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Weekly podcasts from trusted external experts
- Fresh compliance and regulatory content every day
